This article is more than 5 years old. Information may no longer be current.

VIDEO: Speaker provides updates on BRAF/MEK combination therapies

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Jason J. Luke, MD, FACP, assistant professor of Medicine at The University of Chicago Medicine, discussed the current status of the use of combination BRAF/MEK therapy in patients with BRAF-mutated melanoma at HemOnc Today Melanoma and Cutaneous Malignancies.

Luke provided an update on the clinical data that evaluated various combinations of BRAF/MEK inhibitors — including dabrafenib (Tafinlar, GlaxoSmithKline) and trametinib (Mekinist, GlaxoSmithKline), vemurafenib (Zelboraf, Hoffmann-La Roche) and cobimetinib (Cotellic, Genentech), as well as encorafenib (LGX818, Array BioPharma) and binimetinib (MEK162, Array BioPharma).

He also discussed clinical biomarkers that identified patients who derived the best outcomes from each combination therapy, as well as the future of next-generation combination therapies.

“There’s really a lot still to do in melanoma, and we’d still recommend to all patients to consider a clinical trial if it’s a possibility” Luke told HemOnc Today.